Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...

Sotorasib is more cost-effective in treating patients with KRAS G12C non–small cell lung cancer (NSCLC) compared with ...

Zoldonrasib is an innovative tri-complex inhibitor that binds to cyclophilin A, creating a complex that selectively recognizes and inhibits the active, oncogenic RAS G12D (ON) mutant. Revolution ...

Ceralasertib is an oral selective inhibitor of the ATR kinase, an important DNA-repairing protein in tumor cells.

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...

Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...

Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...